Companies › R-Pharm
6 active drug programs in 10 registered trials: 5 Phase 2, 3 Phase 3, 2 Phase 1; Oncology, Cardiovascular, Other, Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Olokizumab Interleukin-6 inhibitor | IL6 | Phase 3 | Polymyalgia Rheumatica; Lung Diseases, Interstitial; Juvenile Idiopathic Arthritis | Apr 2027 |
| RPH-051 HER2-directed monoclonal antibody | ERBB2 | Phase 3 | Locally Advanced Breast Cancer | May 2027 |
| RPH-104 IL-6 receptor antagonist | IL6R | Phase 3 | Idiopathic Recurrent Pericarditis; Familial Mediterranean Fever | Dec 2028 |
| RS-113 | – | Phase 2 | Metastatic Castration-resistant Prostate Cancer | May 2027 |
| Ocrelizumab (RPH-035) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 1 | Multiple Sclerosis | Nov 2027 |
| Panitumumab (RPH-030) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Metastatic Colorectal Cancer | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05092776 | RPH-104 | Phase 2 | Familial Mediterranean Fever | Other | Jan 2025 |
| NCT05673902 | RPH-104 | Phase 3 | Idiopathic Recurrent Pericarditis | Cardiovascular | Jan 2026 |
| NCT07670546 | Olokizumab | Phase 3 | Polymyalgia Rheumatica | Immunology | Apr 2026 |
| NCT06440746 | Olokizumab | Phase 2 | Lung Diseases, Interstitial | Respiratory | Apr 2027 |
| NCT07553988 | RS-113 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | May 2027 |
| NCT07386938 | RPH-051 | Phase 3 | Locally Advanced Breast Cancer | Oncology | May 2027 |
| NCT07597668 | Ocrelizumab (RPH-035) | Phase 1 | Multiple Sclerosis | Neurology | Nov 2027 |
| NCT07543744 | Panitumumab (RPH-030) | Phase 1 | Metastatic Colorectal Cancer | Oncology | Aug 2028 |
| NCT05190991 | RPH-104 | Phase 2 | Familial Mediterranean Fever | Other | Dec 2028 |
| NCT07517575 | Olokizumab | Phase 2 | Juvenile Idiopathic Arthritis | Immunology | Jun 2030 |
Shanghai JMT-Bio BioRay Pharmaceutical Innovent Biopharmaceutical Technology (Hangzhou) Acerta Pharma Suzhou Zelgen Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.